Tectonic Therapeutic, Inc.

Tectonic Therapeutics, Inc. (Nasdaq: TCTX) is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors, or GPCRs. The company operates through its proprietary GEODe™ (GPCRs Engineered for Optimal Discovery) technology platform, which addresses the historical challenges of developing biologic drugs targeting GPCRs by stabilizing pharmacologically relevant receptor conformations, increasing cell surface expression, and enabling large-scale purification for antibody selection.

The company's lead asset, TX45, is an Fc-relaxin fusion molecule in development for Group 2 pulmonary hypertension associated with heart failure with preserved ejection fraction and Group 3 pulmonary hypertension associated with interstitial lung disease. TX45 completed a Phase 1a trial in healthy volunteers and a Phase 1b trial in patients with pulmonary hypertension, with an ongoing Phase 2 APEX trial expected to report topline results in 2026. The company's second product candidate, TX2100, is a VHH-Fc fusion antagonist antibody targeting the APJ receptor for hereditary hemorrhagic telangiectasia, a rare genetic bleeding disorder. TX2100 entered Phase 1a clinical trials in February 2026. A third development program focuses on a bispecific GPCR modulator for fibrotic diseases.

Tectonic's technology platform originated from work conducted at Harvard Medical School, with the company having licensed certain patent rights and technology from Harvard College. The company relies on third-party contract development and manufacturing organizations, including WuXi Biologics, for production of its product candidates. The company has assembled a team with expertise in membrane protein biochemistry, protein engineering, and structural biology to advance its pipeline.

The biotechnology industry is highly competitive, with Tectonic facing competition from major pharmaceutical companies, specialty pharmaceutical firms, and emerging biotechnology companies. The company differentiates itself through its focus on biologic drugs targeting GPCRs and its specialized expertise in GPCR membrane protein biochemistry. As a clinical-stage company, Tectonic has not yet established commercial operations or distribution capabilities. More information about the company is available at www.tectonictherapeutics.com.